Intellectual property rights (IPR) in collaborative drug development in the EU: helping a European public-private partnership deliver - the need for a flexible approach to IPR.

• Jurisdiction: United States
• Date: 01 January 2014
• Author: Laverty, Hugh

The integrated R&D model historically employed by pharmaceutical companies, in which every step of drug development is conducted in-house, is no longer efficient in delivering the new therapies that are needed to address the major health challenges that society faces. over the past decade we have seen companies externalize many of their once core activities in order to regain operational efficiency and feed their dwindling pipelines. These efforts have also been complemented by the establishment of open innovation models leading to the leveraging of external sources of knowledge and know-how, especially in universities and biotechnology companies. The recognition that a single entity is unable to overcome the challenges faced and...